Your session is about to expire
← Back to Search
Quadruple Therapy for Multiple Myeloma (VICD Trial)
VICD Trial Summary
This trial is testing a new cancer drug. It's open-label, which means participants know what drug they're taking, and it's single-arm, which means everyone gets the same treatment. The safety lead-in phase is to make sure the drug is safe before giving it to everyone in the trial.
VICD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVICD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 307 Patients • NCT02990338VICD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I haven't had major surgery within the last two weeks and don't plan any during the study.I do not have any serious heart conditions.You have HIV, hepatitis B, or untreated hepatitis C.My multiple myeloma has affected my brain or spinal cord.I am eligible for a high-dose therapy and stem cell transplant according to my hospital's rules.I am a man and will use effective contraception or practice abstinence.I have a blood disorder.You have a disease that can be measured using certain criteria.I am able to get out of my bed or chair and move around.I have a lung condition that is not well-managed.Certain lab test results at the time of joining the study.I have only had limited treatment for my multiple myeloma.I need immediate treatment for my kidney failure.I have only been diagnosed with or treated for multiple myeloma, or any other cancer I had meets specific conditions.I have multiple myeloma with certain blood cell levels or organ damage.I am a woman who is either postmenopausal, surgically sterile, or willing to use birth control.
- Group 1: Safety Lead-in Cohort A
- Group 2: Expansion Cohort A
- Group 3: Expansion Cohort B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Isatuximab been given the nod of approval from the FDA?
"Despite being in the early stages of clinical testing, isatuximab has sufficient safety data for our team at Power to rate its level of risk as a 2. However, there is yet no evidence that this medication can be effective."
For what maladies is Isatuximab typically prescribed?
"Isatuximab has demonstrated efficacy in treating synovitis, ophthalmia, sympathetic inflammation, and a variety of lung cancers."
Is there any availability to enroll in this clinical experiment?
"Affirmative. Per the clinicaltrials.gov records, this medical trial is currently searching for subjects and was initially posted on November 2nd 2021. Modifications were most recently made on March 14th 2022 and 41 patients are needed between two sites of research."
Can you elucidate which research activities have featured Isatuximab?
"Isatuximab was first experimented with in 1997 by City of Hope Comprehensive Cancer Center. 2326 trials have since been completed, while 1322 are still active and recruiting patients - many occurring in Chicago, Illinois."
Approximately how many volunteers are partaking in this trial?
"Affirmative. Evident on clinicaltrials.gov is this study's active search for participants, which began in November 2nd 2021 and was last modified today (March 14th 2022). This investigation requires 41 individuals from two medical centres."
Share this study with friends
Copy Link
Messenger